The federal government’s most significant cannabis policy shift in half a century is approaching its endgame. The Drug Enforcement Administration’s proposed rule to reclassify cannabis from Schedule I to Schedule III of the Controlled Substances Act — a process set in motion by the Department of Health and Human Services’ August 2023 recommendation — is now in the final stages of administrative review, with a completed rule expected by mid-2026.
For an industry that has operated for over a decade under the legal fiction of state-level permission and federal prohibition, the implications are enormous. But the details matter more than the headlines, and the gap between what rescheduling actually does and what the market seems to believe it does is wide enough to drive a supply truck through.
Where the Rulemaking Stands
The administrative process has been methodical, if slow. After HHS conducted its scientific and medical evaluation and recommended rescheduling in August 2023, the DEA published its proposed rule in the Federal Register in May 2024. This triggered a public comment period that generated over 43,000 submissions — one of the largest in DEA history.
An administrative law judge hearing was convened in early 2025 to address contested factual issues raised during the comment period. That hearing concluded in late 2025, and the ALJ’s recommended decision is now with the DEA Administrator for final consideration. Legal observers expect the final rule to be published between April and July 2026, with an effective date 30 to 60 days after publication.
The rule is widely expected to survive judicial challenge. The DEA is following the same evidence-based reclassification framework it has used for other substances, and the HHS recommendation — which the DEA has historically deferred to on scientific matters — provides a strong administrative record.
What Schedule III Actually Changes
Schedule III classification means the federal government would formally recognize that cannabis has accepted medical use and a moderate to low potential for physical dependence. This is the same category as testosterone, ketamine, and Tylenol with codeine.
What this changes immediately: cannabis businesses would no longer be subject to Internal Revenue Code Section 280E, the provision that prevents businesses trafficking in Schedule I or II substances from deducting ordinary business expenses. This single change is worth billions annually to the industry.
What this does not change: state-by-state legalization frameworks remain intact. Cannabis would still be regulated at the state level for both medical and adult use. Rescheduling does not create a federal legalization framework, does not allow interstate commerce, and does not open the door to cannabis being sold at CVS. The Controlled Substances Act still applies — cannabis would simply be in a less restrictive category. How existing state programs interact with new federal rules remains an open question of federal preemption that regulators and operators will need to navigate carefully.
The distinction matters because the market has periodically priced in a more expansive version of rescheduling than the administrative record supports.
The 280E Tax Question
Section 280E has been the single most punishing financial constraint on legal cannabis operators since the industry’s inception. Under current law, a cannabis company with $10 million in revenue and $7 million in operating expenses can only deduct cost of goods sold — not rent, not salaries, not marketing, not any other normal business expense. The effective federal tax rate for many operators has been 60% to 80%, compared to 21% for a normal corporation.
The removal of 280E through rescheduling would return an estimated $1.8 billion to $2.4 billion annually to the industry, according to analyses by Whitney Economics and Viridian Capital Advisors. For the largest multi-state operators, the impact is transformative. Curaleaf has estimated that 280E relief would improve its annual EBITDA by $60 million to $80 million. Green Thumb Industries has projected similar figures. Trulieve, with its dominant Florida footprint, has modeled 280E relief adding $40 million to $55 million in annual cash flow.
These are not speculative numbers. They represent the difference between an industry that struggles to achieve positive free cash flow and one that can self-fund growth, pay down debt, and attract institutional capital on competitive terms.
How MSOs Are Positioning
The major multi-state operators have been preparing for this moment with varying degrees of aggression. Balance sheet management over the past 18 months tells the story.
Curaleaf has been the most active, renegotiating debt facilities and divesting non-core assets to reduce leverage ahead of rescheduling. The company’s recent sale of its European operations and smaller state licenses reflects a deliberate strategy to concentrate capital in high-margin U.S. markets where 280E relief will have the greatest dollar impact.
Green Thumb Industries has taken a more conservative approach, maintaining a relatively low debt-to-EBITDA ratio and building cash reserves. The company has indicated that post-rescheduling capital allocation will prioritize share buybacks and tuck-in acquisitions over new market entry.
Trulieve has continued its strategy of Florida-first dominance, betting that 280E relief combined with its operational scale — over 130 dispensaries in a single state — will produce outsized returns. The company’s vertical integration model is particularly well-suited to capturing 280E savings, as more of the value chain qualifies for expense deduction under a normal tax regime.
Smaller operators face a different calculus. While 280E relief helps everyone, the operators who have survived the 280E era with intact balance sheets are disproportionately the large MSOs. Many single-state and small multi-state operators have already been forced to sell, merge, or close — and the relief arrives too late for them.
The FDA Path Post-Rescheduling
Perhaps the most underappreciated consequence of Schedule III classification is what it triggers at the Food and Drug Administration. Schedule III substances require FDA approval for medical use, which opens a regulatory pathway that does not currently exist for cannabis.
The FDA has been reluctant to engage on cannabis regulation, issuing only enforcement discretion guidance on CBD and declining to create a comprehensive regulatory framework. Rescheduling forces the issue. If cannabis is a Schedule III substance, the FDA has clear jurisdiction over its medical applications, and the question becomes whether and how existing state medical cannabis programs can coexist with federal pharmaceutical regulation.
This is not a near-term risk. The FDA approval process for any substance takes years, and the agency has signaled that it would not disrupt existing state programs during a transition period. But it is a medium-term structural issue that the industry has largely failed to grapple with, and one that will reshape the competitive landscape as pharmaceutical companies evaluate whether to enter a market that now has a clear federal regulatory path.
Timeline: What Happens Next
The most likely sequence of events from here:
The DEA publishes its final rule between April and July 2026. A 30-to-60-day implementation period follows. Legal challenges are filed but unlikely to result in injunctive relief, given the strength of the administrative record and the HHS scientific recommendation.
280E relief takes effect on the date cannabis is officially reclassified. Operators can begin deducting ordinary business expenses immediately for the current tax year, and many will file amended returns for prior years — though the IRS’s position on retroactive 280E claims remains contested.
The FDA begins a rulemaking process to establish regulatory standards for cannabis products, likely beginning with manufacturing and labeling requirements. This process will take two to three years at minimum.
Congressional action on banking — through the SAFER Banking Act or similar legislation — becomes significantly more likely once cannabis is no longer Schedule I, as the political cover for financial institutions to engage with the industry improves materially.
The net effect is an industry that looks fundamentally different by the end of 2027 than it does today — not because of any single change, but because rescheduling removes the foundational constraint that has distorted every aspect of how cannabis businesses operate, raise capital, and compete.